The increasing complexity of cancer chemotherapy increases the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, E-mail: OncRxSvc@aol.com; or J. Aubrey Waddell, Associate Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, E-mail: waddfour@charter.net.
Get full access to this article
View all access options for this article.
References
1.
CortesJ., KimD W., RostiP.. Dasatinib in patients with chronic myelogenous leukemia in myeloid blast crisis who are imatinib-resistant or imatinibintolerant: results of the CA180006 ‘Start-B’ study. J Clin Oncol (ASCO Annual Meeting Proceedings)2006; 24(18S): 6529.
2.
CoutreS., MartinelliG., DombretH.. Dasatinib in patients with chronic myelogenous leukemia in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia who are imatinib-resistant or intolerant: the CA180015 ‘START-L’ study. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S): 6528.
3.
EvansT.R., MorganJ.A., van den AbbeeleA.D.. Phase 1 dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients with GIST and other solid tumors. J Clin Oncol (ASCO Annual Meeting Proceedings)2005; 23(16S): 3034.
4.
HochhausA., KantarjianM., BaccaraniF.. Dasatinib in patients with chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA 180013 ‘START-C’ study. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S): 6508.
5.
LuoF.R., BarrettY., JiP.. Dasatinib pharmacokinetics correlate with pSRC pharmacodynamics in phase I studies of patients with cancer (CA180002, CA180003). J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S); 3046.
6.
Quintas-CardamaA., KantarjainH., JonesD.. Dasatinib is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib therapy failure. Blood First Edition Paper, prepublished online September 21, 2006; DOI 10.1182/blood-2006-07-035493. Available at: http://www.bloodjournal.org/cgi/content/abstract/blood-2006-07-035493v1. Accessed December 14, 2006.
7.
SawyersC., ShahN.; A Phase I Study of BMS-354825 in Patients with Imatinib-Resistant and Intolerant Accelerated and Blast Phase Chronic Myeloid Leukemia (CML): Results from CA180002. J Clin Oncol (2005 ASCO Annual Meeting Proceedings). 2005; 23(16S): 6520.
8.
ShahN., RousselotP., PasquiniR.. Dasatinib vs high dose imatinib in patients with chronic phase chronic myeloid leukemia resistant to imatinib. Results of the CA 180017 START-R randomized trial. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S): 6507.
TalpazM., ApperleyJ., KimD W.. Dasatinib in patients with accelerated phase chronic myeloid leukemia who are resistant or intolerant to imatinib: results of the CA 180005 ‘START-A’ study. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S): 6526.
11.
TalpazM., KantarjianH., PaquetteR.. A Phase 1 study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia: results from CA 180002. J Clin Oncol (ASCO Annual Meeting Proceedings).2005; 23(16S): 6519.
12.
TalpazM., ShahN., KantarjianH.. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med.2006; 354: 2531–2541.
ArendsR., YangB., SchwabG.. Flexible dosing schedules of panitumumab in cancer patients. J Clin Oncol (ASCO Annual Meeting Proceedings)2005; 23(16S): 3089.
15.
BerlinJ., NeubauerM., SwansonP.Panitumumab antitumor activity in patients with metastatic colorectal cancer expressing ≥ 10% epidermal growth factor receptor. J Clin Oncol (ASCO Annual Meeting Proceedings).2006; 24(18S): 3548.
16.
HechtJ., PoseyJ., TchekmedyuianS.. Panitumumab in combination with 5-fluorouracil, leucovorin, and inrinotecan or FOLFIRI for first-line treatment of metastatic colorectal cancer. ASCO Gastrointestinal Cancers Symposium.2006; 237.
17.
MalikI., HechtJ.R., PatnaikA.. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. J Clin Oncol (ASCO Annual Meeting Proceedings)2005; 23: 3520.
18.
RowinskyE.K., SchwartzG.H., GollobJ.A.. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol.2004; 22: 3003–3015.
19.
WeinerL.M., BelldegrunA., RowinskyE.. Updated results from a dose and schedule study of panitumumab monotherapy, in patients with advanced solid malignancies. J Clin Oncol (ASCO Annual Meeting Proceedings).2005; 23(16S): 3059.
